BioNTech SE Accounts Payable

BioNTech SE (BNTX) currently reports a accounts payable of $650M as of June 2026. That compares with $500M in the prior-year period — up 28.2% year over year. Use the charts on this page to explore BioNTech SE's accounts payable history and peer comparisons.

BioNTech SE's accounts payable increased from $500M to $650M — a 28.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioNTech SE reported $650M in accounts payable as of June 2026. That compares with $500M in the prior-year period — up 28.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $650M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNTech SE, and consider following BNTX for alerts when major investors trade the stock.

BioNTech SE is classified in the Healthcare sector. On accounts payable, it currently shows $650M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNTX with unrelated industries.